Lenalidomide in multiple myeloma.
Treatment options for patients have increased over the last few years, especially with the availability of novel agents for routine care and within clinical trials. Owing to the promising activity seen with lenalidomide in the relapsed/refractory setting, its use has now expanded to induction and maintenance therapy. It is generally well tolerated and the side effects, including hematological toxicity and thromboembolic complications, are usually easily managed. Although new treatments including lenalidomide have increased response rates, the survival has not been strongly impacted. This article will summarize recent data and ongoing clinical trials.
Sirohi
Bhawna
B
Hemato-Oncology, Parkside Oncology Clinic, Wimbledon, UK. myeloma@clara.co.uk
Powles
Ray
R
D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006801:Humans; D000077269:Lenalidomide; D009101:Multiple Myeloma / Q000188:drug therapy*; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use
D000970:Antineoplastic Agents; D013792:Thalidomide; D000077269:Lenalidomide